Welcome to our dedicated page for Xtant Medical Holdings news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical Holdings stock.
Xtant Medical Holdings, Inc. reports developments as a medical technology company focused on surgical solutions for spinal and other orthopedic conditions. Its recurring updates include financial results, commercial activity in orthobiologics, and spinal implant systems used in complex spine, deformity, degenerative, wound care, and sports medicine applications.
Company news also covers product portfolio changes such as Trivium bone graft launches, U.S. distribution rights for HEMOBLAST Bellows, and completed divestitures involving Coflex, CoFix, and Paradigm Spine GmbH. These updates track how Xtant manages its biologics-focused portfolio, distribution channels, and surgical-product commercialization.
Xtant Medical Holdings (NYSE American: XTNT) has announced that its President and CEO, Sean Browne, will present at the Canaccord Musculoskeletal Conference on March 22, 2022, at 2:00 p.m. CT in Chicago. The presentation will focus on the company’s innovative surgical solutions for spinal disorders. Investors can access a live webcast through the company’s website, with a replay available for 90 days post-event. Xtant specializes in orthobiologics and spinal implant systems aimed at enhancing spinal fusion in complex and degenerative procedures.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported financial results for the fourth quarter and full year ended December 31, 2021. The company achieved 4% year-over-year revenue growth, totaling $55.3 million for 2021, driven by private label and OEM orthobiologics sales. The fourth quarter revenue remained stable at $14.0 million. However, gross margin decreased to 55.1% from 64.1% in Q4 2020. Operating expenses rose to $9.6 million in Q4. The net loss for the year improved to $4.8 million, compared to $7.0 million in 2020.
Xtant Medical Holdings (NYSE American: XTNT) will release its financial results for Q4 and the full year ending December 31, 2021, on March 8, 2022, before market open. CEO Sean Browne and Interim CFO Scott Neils will discuss the results in a conference call scheduled for the same day at 9:00 AM ET. Investors can access the call by dialing 877-407-6184 or internationally at 201-389-0877. A replay will be available on their website post-call.
Xtant Medical Holdings, a global medical technology company specializing in spinal disorder solutions, announced that CEO Sean Browne will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A pre-recorded presentation will be available on the company's website starting January 10, 2022, at 7:00 AM Eastern Time and will remain accessible for 30 days. Xtant focuses on designing and commercializing orthobiologics and spinal implant systems for complex spinal procedures.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has appointed Scott Neils as Interim Chief Financial Officer, effective January 3, 2022. Neils, who has 15 years of experience in public accounting and corporate finance, previously served as the Company’s Controller since August 2019. His promotion follows the tenure of Greg Jensen, who has led the finance team for nearly three years. Neils' extensive experience in finance will be pivotal for the Company as it continues to focus on surgical solutions for spinal disorders, ensuring stability during this transitional phase.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported third quarter 2021 financial results, noting a revenue of $13.8 million, a slight decrease from $14.0 million in the prior-year period. The company experienced a net loss of $1.8 million, up from a loss of $1.4 million year-over-year. Gross margin also declined to 52.2% from 66.0%, attributed to changes in sales mix and increased write-downs of excess inventory. Operating expenses rose to $8.6 million due to higher salaries and marketing costs. Xtant continues to expand its distribution network despite challenges from the COVID-19 delta variant.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will announce its Q3 financial results for the period ending September 30, 2021, on November 12, 2021, prior to market opening. A conference call featuring Sean Browne, President and CEO, and Greg Jensen, CFO, is scheduled for 9:00 AM ET the same day. Investors can listen to the call via dial-in or webcast. Xtant Medical specializes in surgical solutions for spinal disorders and offers a range of orthobiologics and spinal implant systems.
Summary not available.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that CEO Sean Browne will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. A pre-recorded presentation will be available on the company's website starting September 13, 2021, at 7:00 AM Eastern Time and will remain accessible for 90 days. Xtant Medical focuses on developing and commercializing spinal implant systems and orthobiologics for spinal fusion.
Xtant Medical Holdings, focused on surgical solutions for spinal disorders, reported a 42% revenue increase to $15.0 million for Q2 2021 compared to the previous year. The gross margin improved to 63.5% from 62.2%. The net loss shrank to $0.7 million or $0.01 per share, significantly better than the $2.5 million loss in Q2 2020. The company closed a $20 million debt refinancing and reported a Non-GAAP Adjusted EBITDA of $0.9 million. Xtant's expansion in sales force and distribution aims to enhance future growth.